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Background
Immunotherapy provides a specific anti-tumour activity
with minimal side effects and thus could be used in treat-
ment of malignant brain tumours. Molecular chaperone
Hsp70 is well known for its ability to stimulate innate and
adaptive anti-cancer immune response. In in vivo studies
we proved the efficacy of the intratumoral delivery of
Hsp70 in the model of intracranial glioma C6 in animals.
Based on our preclinical in vivo data we conducted for the
first time pilot study for assessment of anti-tumour activity
of Hsp70 in patients with brain tumours.
Material and methods
12 patients with diagnosis of malignant brain tumour
were enrolled in clinical trial. Following tumour resection
protein was infused into tumor cavity. Specific immune
response was evaluated in delayed hypersensitivity test
(DTH). Peripheral blood was monitored for possible
changes in lymphocyte subpopulations cytokine levels
and cytolityc activity of NK-cells. Additionally cytokine
production was analyzed in dynamics in liquor after
injection of Hsp70. All patients were monitored for
adverse effects.
Results
Intratumoral injections of Hsp70 were well tolerated in
patients. One patient had complete clinical response and
one partial response documented by radiological findings.
In three patients we observed positive DTH-test. In per-
ipheral blood we observed a shift from cytokines of those
provided by Th2-helpers towards cytokines from Th1-
mediated response (i.e., INF-gamma, TNF-alpha). This
data corresponded to changes in lymphocyte subpopula-
tions. NK-cell activity was not altered.
Conclusions
This pilot study demonstrated for the first time feasibility
and safety of intratumoral delivery of recombinant Hsp70
in cancer patients. Based on our preclinical and clinical
findings we proposed the novel hypothesis of immunomo-
dulatory mechanism of Hsp70. Our results suggest that
purified Hsp70 can induce specific effective anti-tumor
immune response and warrants further investigation in
randomised clinical trials.
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